Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019
November 06, 2019 16:02 ET | Ascendis Pharma A/S
– A single dose of TransCon TLR7/8 Agonist demonstrated sustained localized release of active drug over weeks and potent anti-tumor activity when administered directly into the tumor – ...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Third Quarter 2019 Financial Results and Business Update Conference Call on November 18
November 04, 2019 18:30 ET | Ascendis Pharma A/S
COPENHAGEN, Denmark, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe
October 21, 2019 16:04 ET | Ascendis Pharma A/S
COPENHAGEN, Denmark, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Upcoming Investor Presentation in October
September 26, 2019 08:25 ET | Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting
September 12, 2019 16:20 ET | Ascendis Pharma A/S
– TransCon CNP program gains momentum with initiation of phase 2 ACcomplisH Trial – – Presentations provide new estimate of global birth prevalence and highlight quality-of-life impact of...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Three Investor Presentations in September
August 29, 2019 17:15 ET | Ascendis Pharma A/S
COPENHAGEN, Denmark, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results
August 28, 2019 16:01 ET | Ascendis Pharma A/S
– TransCon hGH moves towards Biologics License Application submission following completion of heiGHt and fliGHt Trials – – Global reach of endocrinology rare disease programs expands – – Conference...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Second Quarter 2019 Financial Results and Business Update Conference Call on August 28
August 14, 2019 17:30 ET | Ascendis Pharma A/S
COPENHAGEN, Denmark, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Participation in August Investor Conferences
July 29, 2019 08:00 ET | Ascendis Pharma A/S
COPENHAGEN, Denmark, July 29, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with Achondroplasia
July 18, 2019 16:12 ET | Ascendis Pharma A/S
COPENHAGEN, Denmark, July 18, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address significant unmet...